Crossmark

Belgian rare diseases plan in clinical pathology: identification of key biochemical diagnostic tests and establishment of reference laboratories and financing conditions

Crossref DOI link: https://doi.org/10.1186/s13023-021-01728-1

Published Online: 2021-02-17

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Vandevelde, Nathalie M. https://orcid.org/0000-0003-0157-7963
Vermeersch, Pieter

Devreese, Katrien M. J.

Vincent, Marie-Françoise

Gulbis, Béatrice

Eyskens, François

Boemer, François

Gothot, André

Van Hoof, Viviane O.

Bonroy, Carolien

Stepman, Hedwig

Martens, Geert A.

Bossuyt, Xavier

Roosens, Laurence

Smet, Julie

Laeremans, Hilde

Weets, Ilse

Minon, Jean-Marc

Vernelen, Kris

Coucke, Wim
Funding

Funding for this research was provided by:

Institut National d'assurance Maladie-Invalidité (W4043.0100.5, W4043.0100.8)
License Information

Text and Data Mining valid from 2021-02-17

Version of Record valid from 2021-02-17
More Information

Article History

Received: 12 June 2020

Accepted: 3 February 2021

First Online: 17 February 2021

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The RDWG members involved in the priority analyses selection work in some of the laboratories performing the analyses covered in this paper.

Document is current

Any future updates will be listed below